References
- Arunlakshana O, Schild HO. (1959). Some quantitative uses of drug antagonists. Br J Pharmacol Chemother, 14, 48–58.
- Cowley AW Jr. (1992). Long-term control of arterial blood pressure. Physiol Rev, 72, 231–300.
- DiBona GF. (1989). Sympathetic nervous system influences on the kidney. Role in hypertension. Am J Hypertens, 2, 119S–124S.
- Drew GM, Whiting SB. (1979). Evidence for two distinct types of postsynaptic α-adrenoceptor in vascular smooth muscle in vivo. Br J Pharmacol, 67, 207–215.
- Du Y, Qiu J, Nelson SH, Wang DH. (1997). Regulation of type 1 ANG II receptor in vascular tissue: Role of α1-adrenoreceptor. Am J Physiol, 273, R1224–R1229.
- Elliott WJ. (2002). Is fixed combination therapy appropriate for initial hypertension treatment? Curr Hypertens Rep, 4, 278–285.
- Global Health Risks. (2009). Mortality and burden of disease attributable to selected major risks, WHO report, I–VI.
- Grassi G. (2001). Renin-angiotensin-sympathetic crosstalks in hypertension: Reappraising the relevance of peripheral interactions. J Hypertens, 19, 1713–1716.
- Hall RA. (2004). beta-adrenergic receptors and their interacting proteins. Semin Cell Dev Biol, 15, 281–288.
- Horn PT, Kohli JD, Listinsky JJ, Goldberg LI. (1982). Regional variation in the α-adrenergic receptors in the canine resistance vessels. Naunyn Schmiedebergs Arch Pharmacol, 318, 166–172.
- Li HT, Long CS, Gray MO, Rokosh DG, Honbo NY, Karliner JS. (1997). Cross talk between angiotensin AT1 and α1-adrenergic receptors: Angiotensin II downregulates α1a-adrenergic receptor subtype mRNA and density in neonatal rat cardiac myocytes. Circ Res, 81, 396–403.
- Mancia G, Saino A, Grassi G. (1995). Interactions between the sympathetic nervous system and the renin-angiotensin system. In: Laragh JG, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York: Raven Press, 399.
- Morphy R, Rankovic Z. (2009). Designing multiple ligands – medicinal chemistry strategies and challenges. Curr Pharm Des, 15, 587–600.
- Paulis L, Unger T. (2010). Novel therapeutic targets for hypertension. Nat Rev Cardiol, 7, 431–441.
- Rang HP, Dale MM, Ritter JM, Flower RJ. (2007). Pharmacology. Philadelphia, USA: Churchill Livingstone.
- Reid IA. (1992). Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol, 262, E763–E778.
- Reit E. (1972). Actions of angiotensin on the adrenal medulla and autonomic ganglia. Fed Proc, 31, 1338–1343.
- Sealey JE, Laragh JH. (1995). The renin-angiotensin-aldosterone system for the normal regulation of blood pressure and sodium and potassium homeostasis. In: Laragh JG, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York: Raven Press, 1763–1797.
- Shepherd JT, Mancia G. (1986). Reflex control of the human cardiovascular system. Rev Physiol Biochem Pharmacol, 105, 1–99.
- Starke K. (1977). Regulation of noradrenaline release by presynaptic receptor systems. Rev Physiol Biochem Pharmacol, 77, 1–124.
- Summers RJ. (1984). Renal α adrenoceptors. Fed Proc, 43, 2917–2922.
- Wolff DW, Buckalew VM Jr, Strandhoy JW. (1984). Renal α1- and α2-adrenoceptor mediated vasoconstriction in dogs: Comparison of phenylephrine, clonidine, and guanabenz. J Cardiovasc Pharmacol, 6 Suppl 5, S793–S798.
- Wolff PW, Gesek FA, Strandhoy JW. (1985). In vivo assessment of rat renal vascular α adrenoceptors [Abstract]. Fed Proc, 44, 76–92.
- Zimmerman BG, Sybertz EJ, Wong PC. (1984). Interaction between sympathetic and renin-angiotensin system. J Hypertens, 2, 581–587.